Ocaliva generic
Ocaliva is an pharmaceutical drug owned by Intercept Pharms Inc. The drug, which was first authorized for market use on 27 May, 2016, contains the active ingredient 'obeticholic acid'.
When will Ocaliva generic be available?
The last of the patents held by Ocaliva will expire on 26 April, 2036. This means that the generic versions of Ocaliva may start to be available from this date onwards.
Ocaliva uses
Ocaliva is primarily used as a treatment of primary biliary cholangitis (PBC). Specifically, it can be used in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
Ocaliva patent expiration
Ocaliva holds 10 drug patents in total, out of which 3 of these have already expired. The last patent will expire on April 26, 2036, paving the way for Ocaliva generics. Below are the details of the patent: